Laura Walker

Laura Walker

Auto-generated profile, based on publicly available information

Laura Walker

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
RGRebecca Garnham
Rebecca Garnham
DGDaniel Geh
Daniel Geh
RNRyan Nelson
Ryan Nelson
ERErik Ramon-Gil
Erik Ramon-Gil
LWLaura Wilson
Laura Wilson
Emma ScottEmma Scott
Emma Scott
Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate cancer. Sialyltransferases have been shown across several solid tumours, including breast, melanoma, colorectal and prostate to promote immune suppression by synthesising sialoglycans, which act as ligands for Siglec receptors. We report that ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) levels negatively correlate with androgen signalling in prostate tumours. We demonstrate that ST3Gal1 plays an important role in modulating tumour immune evasion through the synthesises of sialoglycans with the capacity to engage the Siglec-7 and Siglec-9 immunoreceptors preventing immune clearance of cancer cells. Here, we provide evidence of the expression of Siglec-7/9 ligands and their respective immunoreceptors in prostate tumours. These interactions can be modulated by enzalutamide and may maintain immune suppression in enzalutamide treated tumours. We conclude that the activity of ST3Gal1 is critical to prostate cancer anti-tumour immunity and provide rationale for the use of glyco-immune checkpoint targeting therapies in advanced prostate cancer.

30 September 2024 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Resistance to androgen receptor (AR)–targeted therapies represents a major challenge in prostate cancer. A key mechanism of treatment resistance in patients who progress to castration-resistant prostate cancer (CRPC) is the generation of alternatively spliced AR variants (AR-V). Unlike full-length AR isoforms, AR-Vs are constitutively active and refractory to current receptor-targeting agents and hence drive tumor progression. Identifying regulators of AR-V synthesis may therefore provide new therapeutic opportunities in combination with conventional AR-targeting agents. Our understanding of AR transcript splicing, and the factors that control the synthesis of AR-Vs, remains limited. Although candidate-based approaches have identified a small number of AR-V splicing regulators, an unbiased analysis of splicing factors important for AR-V generation is required to fill an important knowledge gap and furnish the field with novel and tractable targets for prostate cancer treatment. To that end, we conducted a bespoke CRISPR screen to profile splicing factor requirements for AR-V synthesis. MFAP1 and CWC22 were shown to be required for the generation of AR-V mRNA transcripts, and their depletion resulted in reduced AR-V protein abundance and cell proliferation in several CRPC models. Global transcriptomic analysis of MFAP1-depleted cells revealed both AR-dependent and -independent transcriptional impacts, including genes associated with DNA damage response. As such, MFAP1 downregulation sensitized prostate cancer cells to ionizing radiation, suggesting that therapeutically targeting AR-V splicing could provide novel cellular vulnerabilities which can be exploited in CRPC. Implications: We have utilized a CRISPR screening approach to identify key regulators of pathogenic AR splicing in prostate cancer.

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Figure S14. Comparison of Hallmark gene-sets using GSEA shows considerable overlap in Hallmarks regulated by both MFAP1 and AR-V7.

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Figure S18. Knockdown of MFAP1 resensitizes CWR22Rv1 cell lines to enzalutamide, and MFAP1 and CWC22 show no consistent change in expression in PC.

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
AR-V-independent MFAP1-regulated gene list analysed by Enrichr

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Supplementary Table S9 from Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer